Merck
  • Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.

Vaccine (2008-08-07)
Helen A Fletcher, Ansar A Pathan, Tamara K Berthoud, Susanna J Dunachie, Kathryn T Whelan, Nicola C Alder, Clare R Sander, Adrian V S Hill, Helen McShane
要旨

In clinical trials recombinant-modified vaccinia virus Ankara expressing the Mycobacterium tuberculosis antigen 85A (MVA85A) induces approximately 10 times more effector T cells than any other recombinant MVA vaccine. We have found that in BCG primed subjects MVA85A vaccination reduces transforming growth factor beta 1 (TGF-beta1) mRNA in peripheral blood lymphocytes and reduces TGF-beta1 protein in the serum, but increases IFN-gamma ELISPOT responses to the recall antigen SK/SD. TGF-beta1 is essential for the generation of regulatory T cells and we see a correlation across vaccinees between CD4+CD25hiFoxP3+ cells and TGF-beta1 serum levels. This apparent ability to counteract regulatory T cell effects suggests a potential use of MVA85A as an adjuvant for less immunogenic vaccines.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
凍結容器、Nalgene® Mr. Frosty, H × diam. 86 mm × 117 mm